Accession Therapeutics Ltd. has raised £16.6 million (US$20.3 million) in a series A round, as it prepares to take two targeted oncolytic/payload combination viruses into the clinic. At the same time, the company disclosed that the scientist who devised the tumor-only targeting mechanism is Alan Parker, professor of translational virotherapies at Cardiff University.